Do analysts prefer ALZN or EVFM?

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, research analysts plainly believe Alzamend Neuro is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ENSC or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer EVFM or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to EVFM or GOVX?

In the previous week, GeoVax Labs had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.84 beat GeoVax Labs' score of 0.49 indicating that Evofem Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RDHL or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend REVB or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Evofem Biosciences (EVFM) Competitors

$0.0080 0.00 (0.00%)

As of 07/2/2026 03:13 PM Eastern

Compare

EVFM vs. ALZN, ENSC, GOVX, RDHL, and REVB

Should you buy Evofem Biosciences stock or one of its competitors? MarketBeat compares Evofem Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evofem Biosciences include Alzamend Neuro (ALZN), Ensysce Biosciences (ENSC), GeoVax Labs (GOVX), Redhill Biopharma (RDHL), and Revelation Biosciences (REVB). These companies are all part of the "pharmaceutical products" industry.

How does Evofem Biosciences compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Evofem Biosciences had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Alzamend Neuro. Evofem Biosciences' average media sentiment score of 0.84 beat Alzamend Neuro's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Evofem Biosciences	Positive

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, research analysts plainly believe Alzamend Neuro is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alzamend Neuro has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market.

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alzamend Neuro has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Evofem Biosciences has higher revenue and earnings than Alzamend Neuro. Alzamend Neuro is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Summary

Evofem Biosciences beats Alzamend Neuro on 8 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Ensysce Biosciences has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, suggesting that its share price is 233% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than Ensysce Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.86	-$10.18M	-$3.35	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Evofem Biosciences had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Ensysce Biosciences. Evofem Biosciences' average media sentiment score of 0.84 beat Ensysce Biosciences' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Evofem Biosciences	Positive

Evofem Biosciences has a net margin of -46.42% compared to Ensysce Biosciences' net margin of -250.39%. Evofem Biosciences' return on equity of -91.97% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Evofem Biosciences beats Ensysce Biosciences on 9 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to GeoVax Labs?

Evofem Biosciences (NASDAQ:EVFM) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Evofem Biosciences has a beta of -1.33, meaning that its share price is 233% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market.

GeoVax Labs has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
GeoVax Labs	N/A	-709.52%	-399.33%

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Evofem Biosciences has higher revenue and earnings than GeoVax Labs. Evofem Biosciences is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 0.7% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, GeoVax Labs had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for GeoVax Labs and 1 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.84 beat GeoVax Labs' score of 0.49 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evofem Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GeoVax Labs beats Evofem Biosciences on 8 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than Redhill Biopharma. Evofem Biosciences is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Redhill Biopharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Redhill Biopharma's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Redhill Biopharma has a beta of 4.98, meaning that its stock price is 398% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

In the previous week, Evofem Biosciences had 1 more articles in the media than Redhill Biopharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Redhill Biopharma. Evofem Biosciences' average media sentiment score of 0.84 beat Redhill Biopharma's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Evofem Biosciences	Positive

Summary

Redhill Biopharma beats Evofem Biosciences on 10 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Evofem Biosciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.07	N/A

Revelation Biosciences has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-107.65%	-87.98%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by insiders. Comparatively, 0.0% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Evofem Biosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Revelation Biosciences. Evofem Biosciences' average media sentiment score of 0.84 beat Revelation Biosciences' score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Revelation Biosciences	Neutral
Evofem Biosciences	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Evofem Biosciences beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVFM vs. The Competition

Export

Metric	Evofem Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.06M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-0.01	1.66	28.02	24.70
Price / Sales	0.09	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.00	8.17	10.96	6.46
Net Income	$52.98M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Evofem Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVFM Evofem Biosciences	N/A	$0.01 flat	N/A	-20.0%	$1.06M	$11.39M	N/A	120	High Trading Volume
ALZN Alzamend Neuro	3.6113 of 5 stars	$1.12 -6.7%	$28.00 +2,400.0%	-60.9%	$4.57M	N/A	N/A	4	Positive News Gap Down High Trading Volume
ENSC Ensysce Biosciences	0.4159 of 5 stars	$0.30 +4.0%	N/A	-87.7%	$4.46M	$5.07M	N/A	10
GOVX GeoVax Labs	2.6784 of 5 stars	$1.26 -0.8%	$150.00 +11,804.8%	-90.1%	$4.41M	$2.49M	N/A	10
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.83 -1.8%	N/A	-59.7%	$4.39M	$290K	0.00	210	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evofem Biosciences (EVFM) Competitors

EVFM vs. ALZN, ENSC, GOVX, RDHL, and REVB

How does Evofem Biosciences compare to Alzamend Neuro?

Summary

How does Evofem Biosciences compare to Ensysce Biosciences?

Summary

How does Evofem Biosciences compare to GeoVax Labs?

Summary

How does Evofem Biosciences compare to Redhill Biopharma?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evofem Biosciences (EVFM) Competitors

EVFM vs. ALZN, ENSC, GOVX, RDHL, and REVB

How does Evofem Biosciences compare to Alzamend Neuro?

Does the media favor ALZN or EVFM?

Do analysts prefer ALZN or EVFM?

Which has more volatility & risk, ALZN or EVFM?

Do insiders and institutionals hold more shares of ALZN or EVFM?

Is ALZN or EVFM more profitable?

Which has stronger earnings and valuation, ALZN or EVFM?

Summary

How does Evofem Biosciences compare to Ensysce Biosciences?

Which has more risk and volatility, ENSC or EVFM?

Which has higher earnings & valuation, ENSC or EVFM?

Do institutionals & insiders believe in ENSC or EVFM?

Does the media prefer ENSC or EVFM?

Is ENSC or EVFM more profitable?

Do analysts recommend ENSC or EVFM?

Summary

How does Evofem Biosciences compare to GeoVax Labs?

Which has more volatility & risk, EVFM or GOVX?

Is EVFM or GOVX more profitable?

Do analysts prefer EVFM or GOVX?

Which has preferable earnings and valuation, EVFM or GOVX?

Do insiders and institutionals believe in EVFM or GOVX?

Does the media refer more to EVFM or GOVX?

Summary

How does Evofem Biosciences compare to Redhill Biopharma?

Do institutionals and insiders hold more shares of RDHL or EVFM?

Do analysts prefer RDHL or EVFM?

Which has better earnings and valuation, RDHL or EVFM?

Is RDHL or EVFM more profitable?

Which has more volatility and risk, RDHL or EVFM?

Does the media refer more to RDHL or EVFM?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Which has stronger earnings & valuation, REVB or EVFM?

Which has more volatility and risk, REVB or EVFM?

Is REVB or EVFM more profitable?

Do institutionals & insiders have more ownership in REVB or EVFM?

Does the media prefer REVB or EVFM?

Do analysts recommend REVB or EVFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools